Biologic profiling of lymph node negative breast cancers by means of microRNA expression

Modern Pathology

Volumn 23, Issue 12, 2010, Pages 1567-1576

  Janssen, Emiel A M ^a   Slewa, Aida ^a   Gudlaugsson, Einar ^a,b   Jonsdottir, Kristin ^a,b   Skaland, Ivar ^a   Søiland, Hvard ^a   Baak, Jan P A ^a,b,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

breast; cancer; microRNA; profiling

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICRORNA; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SIZE; CLUSTER ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RNA ANALYSIS; RNA HYBRIDIZATION; RNA ISOLATION;

AGED; BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; LYMPH NODES; MICRORNAS; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 78649687693     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.177     Document Type: Article

References (31)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-752.
2. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-1376.
3. Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008;26:3153-3158.
4. Git A, Spiteri I, Blenkiron C, et al. PMC42, a breast progenitor cancer cell line, has normal-like mRNA and microRNA transcriptomes. Breast Cancer Res 2008;10:R54.
5. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008;14:5158-5165.
6. Baak JP, Gudlaugsson E, Skaland I, et al. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat 2009;115:241-254.
7. Baak JP, Kruse AJ, Robboy SJ, et al. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol 2006;59:1017-1028.
8. Andre F, Khalil A, Slimane K, et al. Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. J Clin Oncol 2005;23:2996-3000.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
10. Mothe BR, Stewart BS, Oseroff C, et al. Chronic lympho-cytic choriomeningitis virus infection actively down-regulates CD4+ Tcell responses directed against a broad range of epitopes. J Immunol 2007;179:1058-1067.
11. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007;26:5017-5022.
12. Tavassoli FA, Devilee P, (eds) World Health Organization Classification of Tumors Pathology and Genetics of Tumors of the Breast and Female and Genital Organs. IARC Press: Lyon, 2003.
13. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
14. Baak JP, van Diest PJ, Voorhorst FJ, et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 2005;23:5993-6001.
15. Skaland I, Janssen EA, Gudlaugsson E, et al. Phospho-histone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 2007;20:1307-1315.
16. Bossard C, Jarry A, Colombeix C, et al. Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index. J Clin Pathol 2006;59:706-710.
17. Boenisch T. Formalin-fixed and heat-retrieved tissue antigens: a comparison of their immunoreactivity in experimental antibody diluents. Appl Immunohisto-chem Mol Morphol 2001;9:176-179.
18. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009;15:2711-2722.
19. Baak JP, van Diest PJ, Voorhorst FJ, et al. The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur J Cancer 2007;43:527-535.
20. Lowery AJ, Miller N, Devaney A, et al. MicroRNA signatures predict estrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009;11:R27.
21. Davoren PA, McNeill RE, Lowery AJ, et al. Identification of suitable endogenous control genes for micro-RNA gene expression analysis in human breast cancer. BMC Mol Biol 2008;9:76.
22. Castellano L, Giamas G, Jacob J, et al. The estrogen receptor-alpha- induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA 2009;106:15732-15737.
23. Chen GQ, Zhao ZW, Zhou HY, et al. Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol 2010;27:406-415.
24. Petrocca F, Visone R, Onelli MR, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008;13:272-286.
25. Ivanovska I, Ball AS, Diaz RL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008; 28:2167-2174.
26. Yeung ML, Yasunaga J, Bennasser Y, et al. Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Res 2008;68:8976-8985.
27. Tomasini R, Seux M, Nowak J, et al. TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene 2005;24:8093-8104.
28. Kraus RJ, Ariazi EA, Farrell ML, et al. Estrogen-related receptor alpha 1 actively antagonizes estrogen receptor-regulated transcription in MCF-7 mammary cells. J Biol Chem 2002;277:24826-24834.
29. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998;79:502-508.
30. Wang X, Gocek E, Liu CG, et al. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihy-droxyvitamin D3. Cell Cycle 2009;8:736-741.
31. Park SY, Lee JH, Ha M, et al. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009;16:23-29.